Literature DB >> 17388864

Wegener's granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient.

J L O'Donnell1, V R Stevanovic, C Frampton, L K Stamp, P T Chapman.   

Abstract

BACKGROUND: The aim of the study was to determine whether there was evidence for a geographic gradient in the incidence of Wegener's granulomatosis (WG) and WG-like disease in New Zealand (NZ).
METHODS: The National Minimum Dataset of the Ministry of Health, NZ was searched for individual patient discharges coded by the International Classification of Diseases 10th Revision, Australian Modification as either M301 (polyarteritis with lung involvement, including Churg Strauss and allergic granulomatous angiitis) or M313 (WG, necrotizing respiratory granulomatosis) for the period 1 January 1999 to 31 December 2003. Data were standardized using the 2001 NZ census.
RESULTS: One hundred and ninety-five patients (95 men) were given a first-time discharge code of either M301 (40 patients) or M313 (155 patients). No gender bias was seen. The rate among Europeans was twice that of NZ Maoris or Asians. The rate of disease peaked in the age band 70-79 years and during winter months. A significant positive north-south geographic gradient was present for M313. No difference in the rate of readmission or time to relapse between geographic regions was found for M313.
CONCLUSION: A north-south gradient in the rate of patient discharges given a diagnostic code of M313 (WG, necrotizing respiratory granulomatosis) was present in NZ. This finding supports the hypothesis that there is a latitude-dependent risk factor(s) for WG possibly common to both global hemispheres.

Entities:  

Mesh:

Year:  2007        PMID: 17388864     DOI: 10.1111/j.1445-5994.2006.01297.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  24 in total

Review 1.  Granulomatosis with polyangiitis in childhood.

Authors:  Marinka Twilt; Susanne Benseler; David Cabral
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

2.  ANCA-associated vasculitis in Hispanic Americans: an unrecognized severity.

Authors:  Antoine G Sreih; Ranadeep Mandhadi; Fadi Aldaghlawi; Asad Khan; Vajiha Irshad; Katherine Finn; Joel A Block
Journal:  Clin Rheumatol       Date:  2014-04-22       Impact factor: 2.980

Review 3.  Pathogenesis of ANCA-associated vasculitis.

Authors:  Rodrigo Cartin-Ceba; Tobias Peikert; Ulrich Specks
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

4.  DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans.

Authors:  Yali Cao; John L Schmitz; Jiajin Yang; Susan L Hogan; Donna Bunch; Yichun Hu; Caroline E Jennette; Elisabeth A Berg; Frank C Arnett; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 10.121

5.  Distinction between MPO-ANCA and PR3-ANCA-associated glomerulonephritis in Chinese patients: a retrospective single-center study.

Authors:  Yan Hong; Pengxian Shi; Xia Liu; Liu Yang; Kang Li; Feng Xu; Shaoshan Liang; Zhengzhao Liu; Haitao Zhang; Yinghua Chen; Weixin Hu
Journal:  Clin Rheumatol       Date:  2019-02-08       Impact factor: 2.980

Review 6.  Pathogenesis of ANCA-associated vasculitis.

Authors:  Julia Flint; Matthew D Morgan; Caroline O S Savage
Journal:  Rheum Dis Clin North Am       Date:  2010-06-23       Impact factor: 2.670

7.  Genetically determined severity of anti-myeloperoxidase glomerulonephritis.

Authors:  Hong Xiao; Dominic Ciavatta; David L Aylor; Peiqi Hu; Fernando Pardo-Manuel de Villena; Ronald J Falk; J Charles Jennette
Journal:  Am J Pathol       Date:  2013-02-04       Impact factor: 4.307

Review 8.  ANCA-associated vasculitis with renal involvement.

Authors:  Valentina Binda; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-30       Impact factor: 3.902

Review 9.  The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis.

Authors:  Lisa C Willcocks; Paul A Lyons; Andrew J Rees; Kenneth G C Smith
Journal:  Arthritis Res Ther       Date:  2010-02-15       Impact factor: 5.156

10.  A methodology for a minimum data set for rare diseases to support national centers of excellence for healthcare and research.

Authors:  Rémy Choquet; Meriem Maaroufi; Albane de Carrara; Claude Messiaen; Emmanuel Luigi; Paul Landais
Journal:  J Am Med Inform Assoc       Date:  2014-07-18       Impact factor: 4.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.